Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for production of cell mass containing cytokine-induced killer cell

A technology of killing cells and cytokines, applied in animal cells, vertebrate cells, cell culture active agents, etc., can solve the problems of complicated collection operation and small number of cells, and achieve the effect of high-efficiency treatment effect.

Inactive Publication Date: 2011-04-20
TAKARA HOLDINGS +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, TILs can only be obtained by removing the tumor tissue of the patient, so the collection operation is complicated and the number of cells obtained is very small

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for production of cell mass containing cytokine-induced killer cell
  • Method for production of cell mass containing cytokine-induced killer cell
  • Method for production of cell mass containing cytokine-induced killer cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 Scaled-up culture of CIK cells using fibronectin fragment CH-296

[0073] (1) Isolation of PBMC

[0074] After the blood components were collected from 5 patients who gave informed consent (2 for kidney cancer, 1 for lung cancer, 1 for liver cancer, and 1 for thyroid cancer), the cell fraction containing PBMC was superimposed and centrifuged on Ficoll, and the peripheral blood mononuclear cells in the middle layer were recovered (PBMC).

[0075] (2) Immobilization of anti-human CD3 antibody and CH-296

[0076] Into a T225 flask was added a phosphate-buffered physiological solution containing an anti-human CD3 antibody at a final concentration of 5 μg / mL and CH-296 (Lacronac (registered trademark), manufactured by Takara Biotechnology Co., Ltd.) at a final concentration of 15 μg / mL. 40 mL of saline (PBS) or 40 mL of PBS containing only anti-human CD3 antibody at a final concentration of 5 μg / mL, and then incubated overnight at 4°C. Immediately before use, th...

Embodiment 2

[0090] Example 2 Anti-tumor effect of CIK cells

[0091] (1) Transplantation of CIK cells into cancer patients

[0092] To each cancer patient, the self-derived R-CIKs prepared in Example 1 were implanted twice in 4 days as a round of administration, with an average administration of 3.9×10 10 indivual. All patients received at least 2 rounds of dosing, and one patient received 3 rounds of dosing.

[0093] (2) Anti-tumor effect

[0094] No serious adverse signs associated with cell administration were found in all R-CIKs-administered cancer patients.

[0095] By administration of R-CIKs, improvement of clinical symptoms and recovery of physiological functions were found in all patients. In addition, a significant decrease in calcitonin, a tumor marker, was found in patients with thyroid cancer. In addition, the tumor size of lung cancer patients was measured by PET-CT, and it was found that the tumor shrunk by about 50%.

[0096] In summary, R-CIKs is a very safe cell prep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are: a method for producing a cell mass containing a cytokine-induced killer (CIK) cell, which is characterized by comprising the step of culturing a cell mass containing a cell that can be differentiated into a CIK cell in the presence of a fragment of a fibronectin; and others.

Description

technical field [0001] The present invention relates to a highly efficient cell group containing cytokine-induced killer (CIK) cells in adoptive immunotherapy, a production method of the cell group and the like. The proliferation of regulatory T cells (regulatory T cells; Treg cells) in the cell population containing CIK cells involved in the present invention is inhibited, and can be used for early and advanced cancers and various cell proliferation diseases including hematopoietic cells and solid tumors Treatment. Background technique [0002] In recent years, people have re-examined the treatment methods that cause severe physical pain to patients, such as drug therapy and radiation therapy, and began to pay more and more attention to less painful immunotherapy. This therapy includes, for example, adoptive immunotherapy, which involves culturing the immune-related cells taken out of the body to increase the number of cells and / or enhancing the activity related to the the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/06C12N5/0783
CPCC12N2533/52C12N5/0636C12N2501/58A61P31/00A61P35/00
Inventor 郝希山任秀宝于津浦李慧曹水安秀梅加藤郁之进
Owner TAKARA HOLDINGS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com